The global paracetamol market in 2013 was valued at US$0.8 bn, while the global PAP market was valued at US$0.4 bn. The markets will be, respectively, worth US$1.0 bn and US$0.7 bn in 2022.
One of the key drivers of the global PAP and paracetamol market is the growing awareness regarding the side effects of drugs, which is a precursor to the addition of stringent regulations. These regulations ensure the mitigation of side effects that could prove harmful to a patient. Other drivers of the global PAP and paracetamol market include any sudden epidemics that create a surge in the sales of paracetamol drugs. The global PAP and paracetamol market, except for Europe, can benefit from exporting paracetamol drugs to Europe, as the region no longer manufactures these drugs.
In terms of consumption, North America led the global PAP and paracetamol market in 2013, when the regional paracetamol market was valued at US$394.05 million. The same year, the North America PAP market was worth US$188.9 mn. The North America paracetamol market is expected to reach a value of US$437.1 mn by 2022. The region held a 40.0% share in the global PAP and paracetamol market in 2013, in terms of volume. North America is expected to continue leading the global PAP and paracetamol market due to the large number of PAP and paracetamol manufacturers present in the region, along with the availability of a large number of PAP manufacturers and the advantage that technically advanced manufacturing sites in the region offer. Consumption-wise, Asia Pacific held 24.0% of the global paracetamol market.
The key players in the global PAP and paracetamol market are Zhejiang Hisun Chemical Co., Wuxi Feipeng Imp. & Exp. (Group) Co., Limited, Parchem Fine & Specialty Chemicals, ORGANICA Feinchemie GmbH Wolfen, Mallinckrodt plc, Kemcolour International, Jinan Haohua Industry Co., Ltd., Haihang Industry Co., Ltd., Granules India, BOC Sciences, and Angene International Limited.
